Karolinska Development's Portfolio Company Umecrine Cognition Presents Sustained Effect of Golexanolone in Parkinson's Disease Model

Karolinska Development's portfolio company Umecrine Cognition has published data showing that golexanolone, a drug candidate for Parkinson's disease, provides sustained reversal of neuroinflammation in a Parkinson's disease model. The data, published in Frontiers in Immunology, support the use of golexanolone as a chronic treatment for the disease. The study showed that golexanolone reversed activation of immune cells and reduced inflammation-promoting proteins in the brain.